350-05A

Human Coronary Artery Smooth Muscle Cells: HCASMC, adult

• 同義詞: HCASMC cells
• 分類程式碼代碼: 41106514
• NACRES: NA.81

屬性

• 生物源: human coronary artery (normal, tunica intima and media)
• 品質等級: 100
• 包裝: pkg of 500,000 cells
• 製造商／商標名: Cell Applications, Inc
• 增長模式: Adherent
• 染色體組型: 2n = 46
• 形態學: smooth muscle
• 技術: cell culture | mammalian: suitable
• 相關疾病: diabetes; stroke; cardiovascular diseases
• 運輸包裝: dry ice
• 儲存溫度: −196°C

描述

一般說明

Lot specific orders are not able to be placed through the web. Contact your local sales rep for more details.

Human Coronary Artery Smooth Muscle Cells (HCASMC) provide an excellent model system to study all aspects of cardiovascular function and disease, especially those related to mechanisms of hyperplasia and hypertrophy of intimal smooth muscle cells leading to vascular occlusion in atherosclerosis and stent restenosis.

HCASMC has been utilized in a number of research studies, for example, to:

• Study signaling pathways regulating smooth muscle differentiation (Zhou, 2010); and chronic inflammation of arterial wall that leads to artherosclerosis (Kiyan, 2014)
• Demonstrate that STAT-1 and STAT-3 regulate VEGF production in smooth muscle cells by having opposing effects on HIF-1α expression (Albasanz-Puig, 2012); study the mechanisms of hypoxia and reoxigenation injuries in by demonstrating increased production of ROS and inflammatory cytokines, and further showing that DHA is not beneficial in this type of injuries (Feng, 2012)
• Investigate the gene expression differences between smooth muscle cells from different arteries, underlying their differential response to injuries and proliferation stimuli (Lange, 2013)
• Suggest the hypermethylation of SOCS3 gene as the connection between TNF-α and IGF-1 released in response to mechanical injury during coronary intervention, and the induction of cytokines leading to intimal hyperplasia and restenosis (Dhar, 2013)
• Develop a novel VEGFR/MET-targeted inhibitor with improved antitumor efficacy and decreased toxicity (Fujita, 2013); and investigate novel therapies and drug combinations to achieve optimal target selectivity (Lehar, 2009; Wo-Wong, 2013)
• Develop elastic scaffolds for tissue engineering (Nivison-Smith, 2010, 2012) and novel treatment strategies to prevent stent restenosis by designing new materials (Crowder, 2012), or drug therapies to preferentially inhibit smooth muscle cell growth (O’Neill, 2009; Mociornita, 2013)

Characterization: positive for smooth muscle cell specific alpha-actin expression.

細胞系來源

Artery

應用

vascular research, supply of blood to heart muscle

成分

Basal Medium containing 10% FBS & 10% DMSO

準備報告

• 2nd passage, >500,000 cells in Basal Medium containing 10% FBS & 10% DMSO
• Can be cultured at least 16 doublings

例行更新培養

Please refer to the HCASMC Culture Protocol.

免責聲明

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable